endTB aims to find shorter, less toxic and more effective treatments for ‘multidrug-resistant TB’ (MDR-TB) through:
Covering 18 countries, the project is a partnership between Partners In Health, Médecins Sans Frontières, Interactive Research & Development and financial partners Unitaid and the Transformational Investment Capacity (TIC) of MSF.
You can contact us, or follow us on Twitter.
On 16 July 2025, The Lancet Respiratory Medicine published the results of the Phase III endTB‑Q study, the first clinical trial to focus exclusively on pre‑extensively drug‑resistant tuberculosis (pre‑XDR‑TB).
After 3 years of preparation, the endTB data is now open for requests! The endTB Data Sharing Initiative (eDSI) aims to give ethical, equitable and transparent access to endTB data for a range of users who share the common goal of increasing information to improve care for MDR-TB patients. It will include data from the endTB Observational study, the endTB and endTB-Q clinical trials. Researchers, research institutions, PhD students, and other relevant users are invited to analyze a ready set of data on MDR-TB to benefit people with MDR-TB!
We are proud to share that Lorenzo Guglielmetti has been named to the 2025 TIME100 Health list, honoring the most influential people driving change and innovation in health and medicine globally.
This recognition highlights the significance of the endTB clinical trial led by Lorenzo and others, but also underscores the growing momentum and transformative progress being made in the fight against TB.
